Catalent, Inc. , the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers: To Catalent's Valued Customers, I ...
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is ...
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers, Maselli ...
Pfizer suffered a blow earlier this month when new data showed that its gene therapy for Duchenne muscular dystrophy failed ...
By J. D. Biersdorfer Our critic on new books by Stephanie Wrobel, Lawrence Robbins and Hildur Knútsdóttir. By Sarah Lyall A graphic tribute to the British novelist who documented the blight ...
The contract manufacturer Catalent sent a letter to its customers Monday seeking to reassure them that little will change ...
Door-Knocks, Texts, and Ads, Ads, Ads: Life on the Swing-State Battlefield This year’s campaign offers a vivid reminder of how much the playing field in presidential elections has shrunk, giving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback